share_log

Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $7

Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $7

Chardan Capital维持对Senti Biosciences的买入,将目标价下调至7美元
Benzinga ·  2023/03/23 08:14

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and lowers the price target from $8 to $7.

Chardan Capital分析师Geulah Livshits维持森蒂生物科学公司(纳斯达克:SNTI)的买入,并将目标价从8美元下调至7美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发